Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia

Blood Cancer Journal

Volumn 1, Issue 2, 2011, Pages

  Skavland, J ^a   Jorgensen K M ^a   Hadziavdic, K ^b   Hovland, R ^a   Jonassen, I ^b   Bruserud, O ^a   Gjertsen, B T ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Acute myeloid leukemia; ATRA; Cell signaling; Phosphorylation; Theophylline; Valproic acid

Indexed keywords

CBL PROTEIN; CHEMOKINE RECEPTOR CXCR4; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ERYTHROPOIETIN; FLT3 LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 3; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 12; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN KINASE ZAP 70; RETINOIC ACID; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STEM CELL FACTOR; THEOPHYLLINE; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; EPIGENETICS; FEMALE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT DURATION;

EID: 79952914715     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2011.2     Document Type: Article

References (27)

1. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006; 368: 1894-1907. (Pubitemid 44794525)
2. Lowenberg B. Acute myeloid leukemia: the challenge of capturing disease variety. Hematol Am Soc Hematol Educ Program 2008, 1-11.
3. Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 2005; 104: 2717-2725. (Pubitemid 41798282)
4. Kuendgen A, Strupp C, Aivado M, Bernhardt A, Hildebrandt B, Haas R et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004; 104: 1266-1269. (Pubitemid 39166498)
5. Raffoux E, Chaibi P, Dombret H, Degos L. Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Haematologica 2005; 90: 986-988. (Pubitemid 41020306)
6. Ryningen A, Stapnes C, Lassalle P, Corbascio M, Gjertsen BT, Bruserud O. A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. Leuk Res 2009; 33: 779-787.
7. Montillo M, Ricci F, Tedeschi A, Cafro AM, Nosari AM, Nichelatti M et al. Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia. Leuk Res 2009; 33: 1072-1078.
8. Ryningen A, Stapnes C, Paulsen K, Lassalle P, Gjertsen BT, Bruserud O. In vivo biological effects of ATRA in the treatment of AML. Expert Opin Investig Drugs 2008; 17: 1623-1633.
9. Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M, Zocchi MR. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia 2009; 23: 641-648.
10. Stapnes C, Gjertsen BT, Reikvam H, Bruserud O. Targeted therapy in acute myeloid leukaemia: current status and future directions. Expert Opin Investig Drugs 2009; 18: 433-455.
11. Bellos F, Mahlknecht U. Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients. Onkologie 2008; 31: 629-633.
12. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001; 20: 6969-6978. (Pubitemid 34062289)
13. Wiernik PH, Paietta E, Goloubeva O, Lee SJ, Makower D, Bennett JM et al. Phase II study of theophylline in chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E4998). Leukemia 2004; 18: 1605-1610. (Pubitemid 39386337)
14. Anensen N, Oyan AM, Bourdon JC, Kalland KH, Bruserud O, Gjertsen BT. A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clin Cancer Res 2006; 12: 3985-3992. (Pubitemid 44078084)
15. Oyan AM, Anensen N, Bo TH, Stordrange L, Jonassen I, Bruserud O et al. Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia. BMC Cancer 2009; 9: 77.
16. Hjelle SM, Forthun RB, Haaland I, Reikvam H, Sjoholt G, Bruserud O et al. Clinical proteomics of myeloid leukemia. Genome Med 2010; 2: 41.
17. Abrahamsen JF, Bakken AM, Bruserud O, Gjertsen BT. Flow cytometric measurement of apoptosis and necrosis in cryopreserved PBPC concentrates from patients with malignant diseases. Bone Marrow Transplant 2002; 29: 165-171. (Pubitemid 34144850)
18. Krutzik PO, Nolan GP. Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling. Nat Methods 2006; 3: 361-368.
19. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 2003; 34: 374-378. (Pubitemid 36184095)
20. Benekli M, Xia Z, Donohue KA, Ford LA, Pixley LA, Baer MR et al. Constitutive activity of signal transducer and activator of transcription protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood 2002; 99: 252-257.
21. Gurpur PB, Liu J, Burkin DJ, Kaufman SJ. Valproic acid activates the PI3K/Akt/mTOR pathway in muscle and ameliorates pathology in a mouse model of Duchenne muscular dystrophy. Am J Pathol 2009; 174: 999-1008.
22. Ponchaut S, van Hoof F, Veitch K. Cytochrome aa3 depletion is the cause of the deficient mitochondrial respiration induced by chronic valproate administration. Biochem Pharmacol 1992; 43: 644-647.
23. Silva MF, Ruiter JP, Overmars H, Bootsma AH, van Gennip AH, Jakobs C et al. Complete beta-oxidation of valproate: cleavage of 3-oxovalproyl-CoA by a mitochondrial 3-oxoacyl-CoA thiolase. Biochem J 2002; 362: 755-760. (Pubitemid 34242329)
24. Tong V, Teng XW, Chang TK, Abbott FS. Valproic acid II: effects on oxidative stress, mitochondrial membrane potential, and cytotoxicity in glutathione-depleted rat hepatocytes. Toxicol Sci 2005; 86: 436-443. (Pubitemid 41418656)
25. Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud O, Gjertsen BT et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 2004; 118: 217-228. (Pubitemid 38962577)
26. Glasow A, Prodromou N, Xu K, von Lindern M, Zelent A. Retinoids and myelomonocytic growth factors cooperatively activate RARA and induce human myeloid leukemia cell differentiation via MAP kinase pathways. Blood 2005; 105: 341-349. (Pubitemid 40053102)
27. Hu ZB, Minden MD, McCulloch EA. Regulation of the synthesis of bcl-2 protein by growth factors. Leukemia 1996; 10: 1925-1929. (Pubitemid 27019639)